- Home
- SVRN vs ESLA Comparison
SVRN vs ESLA Comparison
Compare SVRN & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
BUY
Current Price
$26.90
HOLD
Current Price
$0.36
Company Overview
Basic Information| Metric | SVRN | ESLA |
|---|---|---|
| Founded | 2021 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 19.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SVRN | ESLA |
|---|---|---|
| Price | $26.90 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 176.6K | ★ 3.1M |
| Earning Date | 10-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.30 |
| 52 Week High | $74.74 | $3.15 |
Technical Indicators
Market Signals| Indicator | SVRN | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 36.80 |
| Support Level | $4.53 | N/A |
| Resistance Level | $52.00 | $0.51 |
| Average True Range (ATR) | 9.39 | 0.09 |
| MACD | -2.66 | 0.00 |
| Stochastic Oscillator | 4.48 | 1.63 |
Price Performance
Historical Comparison SVRN
ESLA
About SVRN OceanPal Inc.
Svrn Inc operates in the digital asset and blockchain sector, with a focus on the NEAR Protocol. Its activities include managing a digital asset treasury comprising NEAR, promoting commercial adoption of NEAR-based products, and backing, building, and acquiring ventures that serve its mission.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.